The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress

References

• Bao Q, Shen Y, Zhang W. ASO author reflections: metastatic biopsy of osteosarcoma with circulating RNA. Ann Surg Oncol. 2018;25(Suppl S3):936–937.
   PubMedGoogle Scholar
• Heymann D. Metastatic osteosarcoma challenged by regorafenib. Lancet Oncol. 2019;20(1):12–14.
   PubMed Web of Science ®Google Scholar
• Brady SW, Ma X, Bahrami A, et al. The clonal evolution of metastatic osteosarcoma as shaped by cisplatin treatment. Mol Cancer Res. 2019;17(4):895–906.
   PubMed Web of Science ®Google Scholar
• Song K, Song J, Lin K, et al. Survival analysis of patients with metastatic osteosarcoma: a surveillance, epidemiology, and end results population-based study. Int Orthop. 2019;43(8):1983–1991.
   PubMed Web of Science ®Google Scholar
• Bajpai J, Chandrasekharan A, Simha V, et al. Outcomes in treatment-naïve patients with metastatic extremity osteosarcoma treated with OGS-12, a novel non-high-dose methotrexate-based, dose-dense combination chemotherapy, in a tertiary care cancer center. J Glob Oncol. 2018;4:1–10.
   Web of Science ®Google Scholar
• Kopp LM, Malempati S, Krailo M, et al. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the children’s oncology group. Eur J Cancer. 2019;121:177–183.
   PubMed Web of Science ®Google Scholar
• Zou P, Tang R, Luo M. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: a systematic review and meta-analysis. Int Immunopharmacol. 2020;78:106050.
   PubMed Web of Science ®Google Scholar
• Kubo T, Shimose S, Matsuo T, et al. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth. J Orthop Res. 2011;29(5):795–800.
   PubMed Web of Science ®Google Scholar
• Takagi-Kimura M, Yamano T, Tagawa M, et al. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses. Cancer Gene Ther. 2014;21(3):126–132.
   PubMed Web of Science ®Google Scholar
• Blake Z, Marks DK, Gartrell RD, et al. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. J Immunother Cancer. 2018;6(1):25.
   PubMedGoogle Scholar
• Bommareddy PK, Patel A, Hossain S, et al. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017;18(1):1–15.
   PubMed Web of Science ®Google Scholar
• de Golian E, Kwong BY, Swetter SM, et al. Cutaneous complications of targeted melanoma therapy. Curr Treat Options Oncol. 2016;17(11):57.
   PubMed Web of Science ®Google Scholar
• Greig SL. Talimogene Laherparepvec: first global approval. Drugs. 2016;76(1):147–154.
   PubMed Web of Science ®Google Scholar
• Velazquez-Salinas L, Naik S, Pauszek SJ, et al. Oncolytic recombinant Vesicular Stomatitis Virus (VSV) is nonpathogenic and nontransmissible in pigs, a natural host of VSV. Hum Gene Ther Clin Dev. 2017;28(2):108–115.
   PubMed Web of Science ®Google Scholar
• Zhang N, Du B. Reply to rubinstein: is Lgr4 essential for VSV- and VSV-G-pseudotyped lentiviral vector entry to cells? J Biol Chem. 2018;293(1):113.
   PubMed Web of Science ®Google Scholar
• Kimpel J, Urbiola C, Koske I, et al. The oncolytic virus VSV-GP is effective against malignant melanoma. Viruses. 2018;10(3):3.
   Web of Science ®Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4(4):263–275.
   PubMed Web of Science ®Google Scholar
• Cecil A, Gentschev I, Adelfinger M, et al. Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models. Bioengineered. 2019;10(1):190–196.
   PubMed Web of Science ®Google Scholar
• Melcher A. Oncolytic virotherapy: single cycle cures or repeat treatments? (Repeat dosing is crucial!). Mol Ther. 2018;26(8):1875–1876.
   PubMed Web of Science ®Google Scholar
• Malinzi J, Ouifki R, Eladdadi A, et al. Enhancement of chemotherapy using oncolytic virotherapy: mathematical and optimal control analysis. Math Biosci Eng. 2018;15(6):1435–1463.
   PubMed Web of Science ®Google Scholar
• Berg DR, Offord CP, Kemler I, et al. In vitro and in silico multidimensional modeling of oncolytic tumor virotherapy dynamics. PLoS Comput Biol. 2019;15(3):e1006773.
   PubMed Web of Science ®Google Scholar
• Atherton MJ, Stephenson KB, Tzelepis F, et al. Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology. 2018;7(7):e1445459.
   PubMed Web of Science ®Google Scholar
• Fábián Z, Csatary CM, Szeberényi J, et al. p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol. 2007;81(6):2817–2830.
   PubMed Web of Science ®Google Scholar
• Jia X, Chen Y, Zhao X, et al. Oncolytic vaccinia virus inhibits human hepatocellular carcinoma MHCC97-H cell proliferation via endoplasmic reticulum stress,autophagy and Wnt pathways. J Gene Med. 2016;18(9):211–219.
   PubMed Web of Science ®Google Scholar
• Mahoney DJ, Lefebvre C, Allan K, et al. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell. 2011;20(4):443–456.
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell. 2017;168(4):692–706.
   PubMed Web of Science ®Google Scholar
• Song M, Cubillos-Ruiz JR. Endoplasmic reticulum stress responses in intratumoral immune cells: implications for cancer immunotherapy. Trends Immunol. 2019;40(2):128–141.
   PubMed Web of Science ®Google Scholar
• Urra H, Dufey E, Avril T, et al. Endoplasmic reticulum stress and the hallmarks of cancer. Trends Cancer. 2016;2(5):252–262.
   PubMed Web of Science ®Google Scholar
• Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8(3):187–198.
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193–204.
   PubMed Web of Science ®Google Scholar
• Cui W, Wang S, Wang Z, et al. Inhibition of PTEN attenuates endoplasmic reticulum stress and apoptosis via activation of PI3K/AKT pathway in alzheimer’s disease. Neurochem Res. 2017;42(11):3052–3060.
   PubMed Web of Science ®Google Scholar
• Koga T, Suico MA, Shimasaki S, et al. Endoplasmic Reticulum (ER) Stress Induces Sirtuin 1 (SIRT1) expression via the PI3K-Akt-GSK3β signaling pathway and promotes hepatocellular injury. J Biol Chem. 2015;290(51):30366–30374.
   PubMed Web of Science ®Google Scholar
• Wang L, Ning J, Wakimoto H, et al. Oncolytic herpes simplex virus and PI3K Inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells. Mol Ther Oncolytics. 2019;13:58–66.
   PubMed Web of Science ®Google Scholar
• Tong Y, Zhu W, Huang X, et al. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncol Rep. 2014;31(4):1581–1588.
   PubMed Web of Science ®Google Scholar
• Kanai R, Wakimoto H, Martuza RL, et al. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res. 2011;17(11):3686–3696.
   PubMed Web of Science ®Google Scholar
• Balathasan L, Tang VA, Yadollahi B, et al. Activating peripheral innate immunity enables safe and effective oncolytic virotherapy in the brain. Mol Ther Oncolytics. 2017;7:45–56.
   PubMed Web of Science ®Google Scholar
• Beug ST, Pichette SJ, St-Jean M, et al. Combination of IAP antagonists and TNF-α-armed oncolytic viruses induce tumor vascular shutdown and tumor regression. Mol Ther Oncolytics. 2018;10:28–39.
   PubMed Web of Science ®Google Scholar
• Lemay CG, Rintoul JL, Kus A, et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther. 2012;20(9):1791–1799.
   PubMed Web of Science ®Google Scholar
• Ben Yebdri F, Van Grevenynghe J, Tang VA, et al. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis. Mol Ther. 2013;21(11):2043–2053.
   PubMed Web of Science ®Google Scholar
• Yuan P, Dong L, Cheng Q, et al. Prototype foamy virus elicits complete autophagy involving the ER stress-related UPR pathway. Retrovirology. 2017;14(1):16.
   PubMedGoogle Scholar
• Cassidy T, Craig M. Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization. PLoS Comput Biol. 2019;15(11):e1007495.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Puzanov I, Hecht JR, et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015;15(12):1389–1403.
   PubMed Web of Science ®Google Scholar
• Denton NL, Chen CY, Hutzen B, et al. Myelolytic treatments enhance oncolytic herpes virotherapy in models of ewing sarcoma by modulating the immune microenvironment. Mol Ther Oncolytics. 2018;11:62–74.
   PubMed Web of Science ®Google Scholar
• Lastwika KJ, Wilson W 3rd, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76(2):936–937.
   PubMed Web of Science ®Google Scholar
• Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16(1):38–51.
   PubMed Web of Science ®Google Scholar
• Yang L, Lv Q, Liu J, et al. miR-431 regulates granulosa cell function through the IRS2/PI3K/AKT signaling pathway. J Reprod Dev. 2020;66(3):231–239.
   PubMed Web of Science ®Google Scholar
• Yang L, Guan G, Lei L, et al. Palmitic acid induces human osteoblast-like Saos-2 cell apoptosis via endoplasmic reticulum stress and autophagy. Cell Stress Chaperones. 2018;23(6):1283–1294.
   PubMed Web of Science ®Google Scholar
• Verfaillie T, Salazar M, Velasco G, et al. Linking ER stress to autophagy: potential implications for cancer therapy. Int J Cell Biol. 2010;2010:930509.
   PubMedGoogle Scholar
• Namatame N, Tamaki N, Yoshizawa Y, et al. Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines. Oncotarget. 2018;9(80):35141–35161.
   PubMedGoogle Scholar
• Killock D. Skin cancer: t-VEC oncolytic viral therapy shows promise in melanoma. Nat Rev Clin Oncol. 2015;12(8):438.
   PubMed Web of Science ®Google Scholar